Needham & Company LLC Forecasts Strong Price Appreciation for Privia Health Group (NASDAQ:PRVA) Stock

Privia Health Group (NASDAQ:PRVA - Get Free Report) had its target price raised by research analysts at Needham & Company LLC from $25.00 to $30.00 in a research note issued to investors on Friday,Benzinga reports. The firm currently has a "buy" rating on the stock. Needham & Company LLC's price target points to a potential upside of 17.55% from the stock's previous close.

PRVA has been the topic of several other reports. Macquarie initiated coverage on Privia Health Group in a research report on Monday, December 16th. They issued an "outperform" rating and a $25.00 target price on the stock. JMP Securities reiterated a "market outperform" rating and issued a $26.00 price target on shares of Privia Health Group in a research report on Friday, February 14th. Truist Financial boosted their price objective on shares of Privia Health Group from $24.00 to $27.00 and gave the company a "buy" rating in a research report on Friday, November 8th. JPMorgan Chase & Co. raised their target price on Privia Health Group from $27.00 to $28.00 and gave the stock an "overweight" rating in a report on Friday, November 29th. Finally, Stephens reissued an "overweight" rating and set a $26.00 price target on shares of Privia Health Group in a report on Thursday, January 2nd. One research analyst has rated the stock with a hold rating, thirteen have given a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, Privia Health Group has an average rating of "Buy" and a consensus target price of $26.47.

Remove Ads

Privia Health Group Stock Up 2.2 %

PRVA traded up $0.56 during mid-day trading on Friday, reaching $25.52. 1,021,318 shares of the company traded hands, compared to its average volume of 752,447. The stock has a market capitalization of $3.06 billion, a P/E ratio of 255.23, a P/E/G ratio of 3.47 and a beta of 0.87. Privia Health Group has a 52-week low of $15.92 and a 52-week high of $26.04. The company's fifty day moving average price is $22.50 and its 200-day moving average price is $20.64.

Institutional Trading of Privia Health Group

Several hedge funds have recently bought and sold shares of the stock. Nordea Investment Management AB lifted its position in shares of Privia Health Group by 33.1% in the fourth quarter. Nordea Investment Management AB now owns 349,773 shares of the company's stock worth $6,953,000 after buying an additional 86,910 shares in the last quarter. Victory Capital Management Inc. increased its stake in Privia Health Group by 402.9% in the 3rd quarter. Victory Capital Management Inc. now owns 179,049 shares of the company's stock worth $3,260,000 after acquiring an additional 143,446 shares during the last quarter. Franklin Resources Inc. raised its holdings in shares of Privia Health Group by 2.2% during the 3rd quarter. Franklin Resources Inc. now owns 1,300,240 shares of the company's stock worth $23,092,000 after acquiring an additional 28,480 shares in the last quarter. Barclays PLC boosted its position in shares of Privia Health Group by 240.3% during the 3rd quarter. Barclays PLC now owns 224,018 shares of the company's stock valued at $4,079,000 after acquiring an additional 158,188 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in shares of Privia Health Group by 8.4% in the third quarter. JPMorgan Chase & Co. now owns 188,384 shares of the company's stock valued at $3,430,000 after purchasing an additional 14,641 shares in the last quarter. Hedge funds and other institutional investors own 94.48% of the company's stock.

About Privia Health Group

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.